Guideline Statement 26 Systemic (oral) long-term glucocorticoid administration should not be offered
The safety outcomes encompassed the percentage of patients requiring relowering treatment, the incidence of ODSdiagnosed through clinical observation of neurological changes, with MRI of the brain performed for confirmation in suspected casesand the 28-day mortality rate
Ogawa SK, Cohen JY, Hwang D, Uchida N, Watabe-Uchida M
We sense that urgency and are working to move promising therapies through the pipeline and to patients as quickly as possible
What is included matters as much as the number in our program price, which covers provider visits, dose adjustments and check-ins, not just the medication
What exactly does this patch do